arrow
J

José Francisco Kerr Saraiva

Clinical Research Institute of Campinas
H指数:41
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial

司美格鲁肽和心血管风险降低:SELECT试验的中介分析

2026-09-230
OAAI
Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial

米替哌stat抑制髓过氧化物酶在射血分数保留或轻度降低的心力衰竭中的应用:一项随机2b期试验

2026-09-090
PRE
Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEOMINDSET trial

急性冠脉综合征经皮冠状动脉介入治疗后普拉格雷或替格瑞洛单药治疗与双联抗血小板治疗的比较: 来自NEOMINDSET试验的里程碑分析

2025-12-190
OA
2025 Brazilian evidence-based guideline on the management of obesity and prevention of cardiovascular disease and obesity-associated complications: a position statement by five medical societies

2025年巴西基于证据的肥胖管理及心血管疾病预防和肥胖相关并发症预防指南:五家医学学会的立场声明

2025-11-190
OAAI
Lifetime Benefits of Comprehensive Medical Therapy in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

轻度或保留射血分数心力衰竭患者综合药物治疗的全生命周期获益

2025-10-060
PRE
Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged ≥75 Years in STREAM-1 and 2

在STEMI患者中使用半剂量tenectepase的药物侵入性策略: STREAM-1和2中年龄 ≥ 75岁的患者的预设汇总分析

2024-12-010
PRE
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
2024-10-2443
PRE
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up
2024-10-010
PRE
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial
2024-02-018
OAAI
Vilobelimab's effect on mortality in severe COVID-19 ARDS patients: Phase 3 RCT
2023-10-270
PRE
STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial
2023-08-2923
OA
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction A Prespecified Analysis of the DELIVER Randomized Clinical Trial
2023-01-0156
OA
Primary Prevention of Cardiovascular Disease at Community Clinics in the State of Sao Paulo, Brazil: Results from the Epidemiological Information Study of Communities

巴西圣保罗州社区诊所的心血管疾病一级预防: 社区流行病学信息研究的结果

2023-01-011
OAAI
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Anti-C5a抗体 (vilobelimab) 治疗重症,侵入性机械通气新型冠状病毒肺炎患者 (PANAMO): 一项多中心,双盲,随机,安慰剂对照的3期试验

2022-12-0172
OAAI
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

达格列净治疗轻度降低或保留射血分数的心力衰竭

2022-09-221.2K
OA
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
2021-08-1590
OAAI
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
2021-07-29343
OAAI